mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan… - Signal transduction and …, 2022 - nature.com
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting
The continuing emergence of SARS-CoV-2 variants highlights the need to update COVID-19
vaccine compositions. However, immune imprinting induced by vaccination based on the …
vaccine compositions. However, immune imprinting induced by vaccination based on the …
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA. 5 Omicron variant in mice
SM Scheaffer, D Lee, B Whitener, B Ying, K Wu… - Nature medicine, 2023 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines
Immunological memory is the basis of protective immunity provided by vaccines and
previous infections. Immunological memory can develop from multiple branches of the …
previous infections. Immunological memory can develop from multiple branches of the …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
[HTML][HTML] Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been
deployed globally. We investigated whether antibodies stimulated by mRNA vaccination …
deployed globally. We investigated whether antibodies stimulated by mRNA vaccination …
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
Omicron BA. 1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
J Quandt, A Muik, N Salisch, BG Lui, S Lutz… - Science …, 2022 - science.org
Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA. 1 breakthrough …
(SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA. 1 breakthrough …
Homologous and heterologous Covid-19 booster vaccinations
RL Atmar, KE Lyke, ME Deming… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective …
have received emergency use authorization in the United States are highly effective …